The composition of the drug:
active substance: 1 tablet contains ethyl ether 6-bromine-5-hydroxy-1-methyl - 4-dimethyl amine ethyl-2-peltomaki indole-3-carboxylic acid hydro chloride monohydrate (in terms of 100 % substance) 50 mg or 100 mg;
auxiliary substances: potato starch, g of ethyl cellulose, calcium stearate, silica colloidal anhydrous, "Opadry II" 85 F white.
Dosage form. Tablets, film-coated.
Tablets, film-coated, biconvex shaped white or white with a cream shade.
The name and location of manufacturer. ZAO "Pharmaceutical firm "Darnitsa". Ukraine, 02093, Kiev, vul. Boryspil, 13.
Pharmacotherapeutic group. Antivirals for systemic use.
Code ATX. J05A X.
The pharmacological properties.
Antiviral agent with immunomodulatory effects, active against influenza viruses A and b and other acute respiratory viral infections (ARVI). Mustat acts on early stages of virus replication at the stage of virus penetration into the cell. Virusspecific inhibits the process of merging the lipid shell of virus with the cell membranes due to the interaction with hemagglutinin of the virus, increasing the resistance of hemagglutinin to conformational changes. The drug induces interferon and enhances phagocytic function of macrophages. Reduces the incidence of complications associated with viral infection, and cases of exacerbation of chronic diseases.
Therapeutic efficacy in viral infections is manifested in the reduction of intoxication and clinical symptoms, reduced the duration of disease.
The vehicle belongs to low-toxic drugs (LD50 > 4 g/kg). No negative impact on the human body when administered orally in the recommended doses.
The drug is rapidly absorbed in the digestive tract. Maximum concentration is reached after 1.2 hours after administration of the dose of 0.05 g at 1.5 hours after administration of the dose of 0.1 g. Metabolised in the liver. The half excretion is 17 – 21 hours. Approximately 40% of the drug is excreted unaltered in feces (38.9 %) and urine 0,12 %). During the first days excreted 90 % of the dose.
Indications for use. Prevention and treatment of influenza and acute respiratory viral infections, including complicated. In the complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection.
In the complex therapy of acute intestinal infections of the mouth viral etiology in children older than 2 years.
Contraindications. Hyper sensitivity to the drug; children up to age 2 years.
Special warnings. The drug does not show a Central neurotropic activity and can be used in medical practice as a preventive measure for healthy persons of various professions that require greater attention and coordination of movements (drivers, etc).
Use during pregnancy or breast-feeding. Clinical data on the safety and efficacy of Moscato during pregnancy and lactation are not available. Perhaps the use during pregnancy in cases where the benefit to the mother outweighs the potential risk to the fetus. If necessary, use of the drug during lactation breastfeeding should be discontinued.
The ability to influence the rate of reaction at management of motor transport or operating other mechanisms. The drug does not affect the velocity of neuromuscular conduction, it in recommended doses to apply to persons managing vehicles and operating other mechanisms.
Children. The drug is used in children aged 2 years.
Method of application and doses. Mustat taken orally, before meals.
With the purpose of nonspecific prophylaxis.
Persons in contact with patients with influenza and other viral respiratory infection: children from 2 to 6 years appoint 50 mg, 6-12 years 100 mg, children aged from 12 years and adults – 200 mg once a day for 10 to 14 days.
During the epidemic of influenza and SARS, to prevent exacerbations of chronic bronchitis and recurrent herpes:
children aged 2 to 6 years appoint 50 mg, children 6 to 12 years – 100 mg, children aged from 12 years and adults – 200 mg 2 times per week for 3 weeks.
With the medical purpose.
Influenza and other ARVI without complications:
children aged 2 to 6 years appoint 50 mg, 6-12 years 100 mg, children aged from 12 years and adults – 200 mg 4 times a day (every 6 hours) for 3 to 5 days.
Influenza and other ARVI, complicated by bronchitis, pneumonia:
children aged 2 to 6 years appoint 50 mg, children 6 to 12 years – 100 mg, children aged from 12 years and adults – 200 mg 4 times a day (every 6 hours) for 5 days, then a single dose once a week for 4 weeks.
In the complex therapy of chronic bronchitis and recurrent herpetic infection:
children aged 2 to 6 years appoint 50 mg, children 6 to 12 years – 100 mg, children over 12 and adults – 200 mg 4 times a day (every 6 hours) for 5 - 7 days, then a single dose twice a week for 4 weeks.
In the complex treatment of intestinal infections of the mouth viral etiology in children over 2 years: children 2 to 6 years appoint 50 mg, children 6 to 12 years – 100 mg, children over 12 years – 200 mg 4 times a day (every 6 hours) for 5 weeks.
Overdose. Overdose Mustata there were no reports. If the patient has taken too large a dose of medication (greater than daily), it is necessary to consult a doctor. The therapy is symptomatic.
Side effects. Allergic reactions.
In case of any unusual reactions, be sure to consult your doctor regarding further use of the drug.
Interaction with other medicinal products and other forms of interaction. When applying with other drugs negative side effects were not observed. The interaction is not known yet.
The expiration date. 2 years.
The storage conditions. Keep out of the reach of children in original container at temperature not exceeding 25 °C.
Packing. 10 tablets are in a blister; 1 blister in a pack.